1. Show article details.

    Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Business Wire – 8:00 AM ET 06/30/2020

    Magenta Therapeutics, Inc. (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,125,000 shares, at...

  2. Show article details.

    BRIEF-Magenta Therapeutics Announces Pricing Of Public Offering

    Reuters – 8:48 PM ET 06/24/2020

    Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING. * SAYS PUBLIC OFFERING OF 7.50 MILLION COMMON SHARES PRICED AT $8.00PER SHARE Source text for Eikon: Further company coverage:

  3. Show article details.

    Magenta Therapeutics Announces Pricing of Public Offering

    Business Wire – 8:20 PM ET 06/24/2020

    Magenta Therapeutics, Inc. (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.00 per share. Goldman Sachs & Co. LLC and Cowen are acting as joint bookrunning managers for the offering.

  4. Show article details.

    BRIEF-Magenta Therapeutics Launches Proposed Public Offering

    Reuters – 4:25 PM ET 06/24/2020

    Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS LAUNCHES PROPOSED PUBLIC OFFERING. * MAGENTA THERAPEUTICS (MGTA) - COMMENCED UNDERWRITTEN PUBLIC OFFERING OF $60 MILLION OF ITS COMMON STOCK. * MAGENTA THERAPEUTICS (MGTA) - INTENDS TO USE PROCEEDS TO ADVANCE CLINICAL, EARLIER STAGE PROGRAMS Source text for Eikon: Further company coverage:

  5. Show article details.

    Magenta Therapeutics Launches Proposed Public Offering

    Business Wire – 4:21 PM ET 06/24/2020

    Magenta Therapeutics, Inc. (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has commenced an underwritten public offering of $60 million of its common stock. Goldman Sachs & Co. LLC and Cowen are acting as joint bookrunning managers for the offering.

  6. Show article details.

    BRIEF-Magenta And Beam Join To Evaluate MGTA-117 As Conditioning Regimen For Base Editing Therapies

    Reuters – 6:45 AM ET 06/15/2020

    Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS AND BEAM THERAPEUTICS ANNOUNCE COLLABORATION TO EVALUATE TARGETED ANTIBODY-DRUG CONJUGATE MGTA-117 AS CONDITIONING REGIMEN FOR BASE EDITING THERAPIES. * MAGENTA THERAPEUTICS (MGTA) - CO, BEAM THERAPEUTICS ANNOUNCED NON-EXCLUSIVE COLLABORATION AGREEMENT TO EVALUATE POTENTIAL UTILITY OF MGTA-117 Source text for Eikon: Further company coverage:

  7. Show article details.

    Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies

    Business Wire – 6:00 AM ET 06/15/2020

    – MGTA-117 conditioning for precise depletion of cells in the bone marrow could potentially increase patients’ benefit from Beam’s base editing therapies for sickle cell disease and beta thalassemia – Magenta Therapeutics (MGTA) and Beam Therapeutics (BEAM) today announced a non-exclusive research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel targeted ADC...

  8. Show article details.

    BRIEF-Magenta Therapeutics Inc - Made Strategic Decision To Discontinue Enrollment In Phase 2 Study Of Mgta-456 In Inherited Metabolic Disorders

    Reuters – 8:43 AM ET 06/11/2020

    Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS PROVIDES PORTFOLIO UPDATE: STEM CELL MOBILIZATION AND CONDITIONING PROGRAMS PRIORITIZED AND ADVANCING TOWARD CLINICAL MILESTONES. * Magenta Therapeutics Inc (MGTA) - MGTA-145 FIRST-LINE MOBILIZATION PROGRAM TO MOVE INTO PHASE 2 STUDIES IN AUTOLOGOUS AND ALLOGENEIC PATIENTS IN 2020.

  9. Show article details.

    Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones

    Business Wire – 7:30 AM ET 06/11/2020

    — MGTA-145 first-line mobilization program to move into Phase 2 studies in autologous and allogeneic patients in 2020, including allogeneic study in newly announced collaboration with National Marrow Donor Program®/Be The Match® — — based conditioning program on track for initial clinical data in 2021; research and clinical collaboration with AVROBIO announced May 2020 to jointly evaluate pote...

  10. Show article details.

    BRIEF-Magenta Therapeutics Announces Collaboration With The National Marrow Donor Program

    Reuters – 7:12 AM ET 06/11/2020

    Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS ANNOUNCES COLLABORATION WITH THE NATIONAL MARROW DONOR PROGRAM/BE THE MATCH TO ADVANCE DEVELOPMENT OF MGTA-145 FOR FIRST-LINE MOBILIZATION OF STEM CELLS FROM HEALTHY DONORS AND SUBSEQUENT PATIENT TRANSPLANT.

  11. Show article details.

    Magenta Therapeutics Announces Collaboration with the National Marrow Donor Program/Be The Match to Advance Development of MGTA-145 for First-Line Mobilization of Stem Cells from Healthy Donors and Subsequent Patient Transplant

    Business Wire – 7:00 AM ET 06/11/2020

    Collaboration focuses on clinical development of MGTA-145 for stem cell mobilization in allogeneic transplant in patients with blood cancers Plan to initiate a Phase II trial of MGTA-145 in matched related donors for patients undergoing allogeneic transplant CAMBRIDGE, Mass.

  12. Show article details.

    Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences

    Business Wire – 4:30 PM ET 06/08/2020

    Magenta Therapeutics (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in a fireside chat and hold investor meetings at the 41st annual Goldman Sachs Healthcare Conference on June 11th, 2020.

  13. Show article details.

    BRIEF-Magenta Therapeutics Presents Data Supporting Immune Reset For Autoimmune Diseases

    Reuters – 8:32 AM ET 06/05/2020

    Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS PRESENTS DATA SUPPORTING IMMUNE RESET FOR AUTOIMMUNE DISEASES Source text for Eikon: Further company coverage:

  14. Show article details.

    Magenta Therapeutics Presents Data Supporting Immune Reset for Autoimmune Diseases

    Business Wire – 8:30 AM ET 06/05/2020

    -- Single dose of CD45-ADC shown to remove disease-causing cells and halt disease in models of multiple sclerosis, systemic sclerosis and inflammatory arthritis -- -- MGTA-145 Phase 1 clinical data for stem cell mobilization provide a strong rationale for studying in patients with autoimmune diseases -- CAMBRIDGE, Mass. “Millions of patients worldwide live with debilitating autoimmune diseases.

  15. Show article details.

    BRIEF-Magenta Therapeutics Presents Data Demonstrating Cells Mobilized With MGTA-145 In A Phase I Trial Are Effective In Gene Therapy Settings

    Reuters – 8:25 AM ET 05/14/2020

    Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS PRESENTS DATA AT ANNUAL MEETING OF AMERICAN SOCIETY OF GENE AND CELL THERAPY DEMONSTRATING CELLS MOBILIZED WITH MGTA-145 IN A PHASE I TRIAL ARE EFFECTIVE IN GENE THERAPY SETTINGS. * MAGENTA THERAPEUTICS (MGTA) - MGTA-145 WAS SHOWN TO BE RAPID, RELIABLE, EFFICIENT AND G-CSF-FREE METHOD TO OBTAIN HIGH NUMBERS OF FUNCTIONAL HSCS IN PHASE 1 TRIAL.

  16. Show article details.

    Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a Phase I Trial Are Effective in Gene Therapy Settings

    Business Wire – 8:00 AM ET 05/14/2020

    – MGTA-145 was shown to be a rapid, reliable, efficient and G-CSF-free method to obtain high numbers of functional HSCs in a Phase 1 trial; the cells could be gene modified and engraft in animals.

  17. Show article details.

    BRIEF-Magenta Therapeutics Reports Recent Business Highlights And Q1 Financial Results

    Reuters – 8:20 AM ET 05/07/2020

    Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER FINANCIAL RESULTS. * Magenta Therapeutics Inc (MGTA) - NET LOSS WAS $20.0 MILLION FOR Q1 OF 2020, COMPARED TO NET LOSS OF $14.8 MILLION FOR Q1 OF 2019 Source text for Eikon: Further company coverage:

  18. Show article details.

    Magenta Therapeutics Reports Recent Business Highlights and First Quarter Financial Results

    Business Wire – 7:30 AM ET 05/07/2020

    – MGTA-117 ADC clinical candidate for immune and blood system reset has demonstrated broad therapeutic index; on track for initial clinical data in 2021 – – Announced research and clinical collaboration with AVROBIO to evaluate potential utility of MGTA-117 antibody-drug conjugate as conditioning regimen in gene therapy setting – – Completed dosing in Phase 1 MGTA-145 trial, demonstrating rapi...

  19. Show article details.

    BRIEF-Magenta Therapeutics And Avrobio Collaborate To Evaluate Targeted Antibody-Drug Conjugate

    Reuters – 8:06 AM ET 05/06/2020

    AVROBIO Inc (AVRO): * MAGENTA THERAPEUTICS AND AVROBIO ANNOUNCE COLLABORATION TO EVALUATE TARGETED ANTIBODY-DRUG CONJUGATE AS A POTENTIAL CONDITIONING REGIMEN FOR LENTIVIRAL GENE THERAPIES. * MAGENTA THERAPEUTICS INC (MGTA) - CO & AVROBIO WILL JOINTLY EVALUATE MGTA-117 IN CONJUNCTION WITH ONE OR MORE OF AVROBIO'S INVESTIGATIONAL GENE THERAPIES.

  20. Show article details.

    Magenta Therapeutics and AVROBIO Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies

    Business Wire – 7:00 AM ET 05/06/2020

    Collaboration focuses on advancing innovation with antibody-drug conjugate-based conditioning for lentiviral gene therapies Under the collaboration, Magenta and AVROBIO (AVRO) will jointly evaluate MGTA-117 in conjunction with one or more of AVROBIO’s investigational gene therapies Each company will retain all commercial rights to their respective programs Magenta to hold business update conference ca...

Page:

Today's and Upcoming Events

  • Aug
    10

    MGTA to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    07

    MGTA announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.